Abstract:GPR40 is primarily expressed in pancreatic islet 8 -cells, and its activation by endogenous ligands of medium to long-chain free fatty acids or synthetic agonists is clinically proved to improve glycemic control by stimulating glucose-dependent insulin secretion. However, most of the reported agonists are highly lipophilic, which might cause lipotoxicity and the off-target effects in CNS. Particularly, the withdrawal of TAK-875 from clinical trials phase III due to liver toxicity concern threw doubt over the long-term safety of targeting GPR40. Improving the efficacy and the selectivity, thus enlarging the therapeutic window would provide an alternative to develop safe GPR40-targeted therapeutics. Herein, by employing an innovative "three-in-one" pharmacophore drug design strategy, the optimal structural features for GPR40 agonist was integrated into one functional group of sulfoxide, which was incorporated into the 8 -position of the propanoic acid core pharmacophore. As a result, the confor-mational constraint, polarity as well as chirality endowed by the sulfoxide significantly enhanced the efficacy, selectivity and ADMET properties of the novel (S)-2-(phenylsulfinyl)acetic acid-based GPR40 agonists. The lead compounds (S)-4a and (S)-4s exhibited robust plasma glucose-lowering effects and insulinotropic action during an oral glucose tolerance test in C57/BL6 mice, excellent pharmacokinetic profile and little hepatobiliary transporter inhibition, marginal cell toxicities against human primary hepatocyte at 100 mu M.

G蛋白偶联受体40激动剂TAK-875亚砜类似物的合成、绝对构型确证及生物活性研究

Sulfoxide Analogs of Tak-875 As G Protein Coupled Receptor 40 Agonists: Synthesis, Determination of Absolute Configuration and Biological Activity

Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.

In Vivo Pharmacokinetic Study and Oral Glucose Tolerance Test of Sulfoxide Analogs of GPR40 Agonist TAK‐875

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

Discovery of Orally Effective and Safe GPR40 Agonists by Incorporating a Chiral, Rigid and Polar Sulfoxide into Β-Position to the Carboxylic Acid.

GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: the Biological Characteristics and the Chemical Space

Optimization of GPR40 Agonists for Type 2 Diabetes.

In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of <scp>GPR40</scp> agonist <scp>TAK</scp> ‐875

Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

Design and Biological Evaluation of Tetrahydropyridine Derivatives As Novel Human GPR119 Agonists

Discovery of Two flavonoids as Agonists of G Protein-Coupled Receptor-35

Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.

Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into 8-position to the carboxylic acid

Discovery And Optimization Of Potent Gpr40 Full Agonists Containing Tricyclic Spirocycles

Insight into Analysis of Interactions of GW9508 to Wild-Type and H86F and H137F GPR40: A Combined QM/MM Study and Pharmacophore Modeling

De novo Design of G Protein-Coupled Receptor 40 Peptide Agonists for Type 2 Diabetes Mellitus Based on Artificial Intelligence and Site-Directed Mutagenesis

Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists.

Structure of human GPR119-Gs complex binding APD597 and characterization of GPR119 binding agonists

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold